C-10 Carbon-Substituted Artemisinin-Like Trioxane Compounds Having Antimalarial, Antiproliferative and Antitumor Activities

Artemisinin is usually administered for the treatment of multi-drug resistant malaria. However, studies have determined that artemisinin not only possesses excellent anti-malarial properties but also considerable anti-cancer activities. Scientists at JHU have described a procedure for the production of enantiomerically pure monomeric and dimeric C-10 non-acetyl derivatives of natural artemisinin that are more stable than previous artemisinin derivatives towards hydrolysis. The series of novel hydrolytically stable artemisinin-like trioxane compounds also exhibit highly potent anticancer activities and long lasting anti-malarial effects. Description (Set) Proposed Use (Set) Each year approximately 200-300 million people are infected with malaria and over 1 million die. In patients with severe and complicated disease the mortality rate is between 20-50%. The artemisinin-like trioxane compounds described in this invention may be used alone, or in combination therapy regimes for the treatment of multi-drug resistant malaria. Likewise, artemisinin-like trioxane compounds may be used as a chemotherapeutic agent in the treatment of cancer, now the leading cause of death in the US today.
Patent (Set) 6,297,272

Patents:
US 6,297,272

Inventor(s): Shapiro, Teresa A.

Type of Offer: Licensing



« More Medical Patents

---